Comprehensive research guide to growth hormone secretagogues — Sermorelin, CJC-1295, Tesamorelin (GHRH analogues) and Ipamorelin (ghrelin mimetic). Mechanisms, clinical data, comparison table, and FAQ with PubMed citations.
Last updated Jun 11, 2026·12 min read
If you have spent any time researching growth hormone secretagogues, you have probably watched forum threads treat Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation , CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue , Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation , and Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue as interchangeable options on a menu. That assumption is the first mistake — because these four compounds differ in receptor targets, duration of action, evidence depth, and even legal status, and those differences decide which tool answers which research question.
The shared logic starts with biology: your body does not drip growth hormone out continuously. It releases GH in pulses — sharp bursts timed mainly during deep sleep and after intense physical exertion — orchestrated by a precisely calibrated conversation between the hypothalamus, the pituitary gland, and peripheral tissues. Secretagogues interest researchers because they amplify the pituitary's own production rather than replacing it from outside.
Two molecular pathways drive that pulsatility. Growth hormone-releasing hormone (GHRH), released from the hypothalamus, pushes GH synthesis and initial release through GHRH receptors on pituitary somatotrophs. Ghrelin, a peptide produced primarily in the stomach lining, amplifies those pulses through a separate receptor — the GHS-R1a. They are complements, not duplicates, converging on the same pituitary cells through distinct intracellular signaling cascades.
This guide follows both pathways through four compounds: **Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation and CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue , GHRH analogues distinguished mainly by how long each survives in the bloodstream; Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation , the modified GHRH analogue that carries the distinction of being the only compound in this class with full FDA approval for a specific clinical indication; and Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue **, a ghrelin mimetic engineered for exceptional receptor selectivity.
By the end you'll know how each was engineered, what the human and preclinical data actually show, and where the regulatory lines sit. One transparency note woven in before the compound sections rather than bolted onto the end: apart from Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation 's approved indication, none of these compounds is approved for general therapeutic use, and everything below reflects published research rather than guidance for personal use.
Start with Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation — the shortest-lived of the four, and in some ways the most physiologically faithful.
I.Overview
Here is the rhythm worth internalizing before any compound discussion: the pituitary releases growth hormone in discrete pulses — typically 6 to 12 per day, with the largest arriving about an hour after sleep onset during slow-wave sleep stages 3 and 4 PMID: 18031173 . That single nocturnal pulse accounts for roughly 70% of daily GH secretion in young adults — meaning most of the day's growth hormone business happens while you sleep. Two opposing hypothalamic signals set the timing: GHRH, the accelerator, and somatostatin, the brake. Ghrelin, produced mainly in the stomach, adds a third, independent signal that amplifies pulses through the GHS-R1a receptor.
With age, both pulse amplitude and frequency decline — a well-documented process called somatopause that begins in the third or fourth decade of life PMID: 16352683 . The decline parallels rising fat mass, shrinking lean mass, falling bone density, and slower cellular repair. Secretagogues attract research attention precisely because they address this decline at its source: the pituitary's diminishing responsiveness to hypothalamic signals.
GHRH analogues bind the GHRH receptor on somatotrophs — a G-protein-coupled receptor that activates adenylyl cyclase, raises cyclic AMP (cAMP), switches on protein kinase A, and triggers both GH gene transcription and calcium-dependent exocytosis of secretory granules. The engineering question separating the analogues is survival. Native GHRH lasts only 2–5 minutes before dipeptidyl peptidase-4 (DPP-4) and other circulating proteases shred it; each analogue solves that problem differently — Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation by minimal modification, CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue by albumin-binding technology, Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation by N-terminal stabilization.
Ghrelin mimetics enter through an entirely separate door. The GHS-R1a receptor signals through the Gq/11 pathway — activating phospholipase C, raising IP3 and diacylglycerol (DAG), and releasing calcium from intracellular stores. That calcium surge triggers GH exocytosis within minutes. Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue , the most selective mimetic studied, produces sharp, pulsatile GH peaks without the cortisol and ACTH elevation that earlier compounds like GHRP-2 and GHRP-6 GHRP-6 growth hormone secretagogue (GHS) / ghrelin receptor agonist Ghrelin mimetic hexapeptide — strongest appetite stimulation among GHRPs caused PMID: 18031173 .
And when both pathways fire together, something notable happens: synergistic GH release, exceeding what either pathway achieves alone PMID: 18031173 — because GHS-R1a activation partially suppresses somatostatin, releasing the brake while the GHRH signal presses the accelerator. That dual-pathway logic is the pharmacological foundation for combining a GHRH analogue with a ghrelin mimetic, examined later in this guide.
Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation began as a trimming exercise. Native GHRH runs 44 amino acids, but research established that the first 29 carry full receptor-binding and GH-releasing activity — so researchers synthesized that minimal segment, GHRH 1-29, as the smallest fully functional unit of the system.
Its résumé is unmatched in one respect: Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation was the first GHRH analogue to receive FDA approval, granted in 1997 under the brand name Geref for diagnosing and treating pediatric growth hormone deficiency. The branded product left the U.S. market in 2008 — not over safety concerns but over commercial ones — and compounded Sermorelin has remained available since.
Pharmacologically, everything revolves around brevity: a half-life of 11–12 minutes after either intravenous or subcutaneous administration. Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation keeps the native DPP-4 cleavage site that circulating proteases exploit, so it degrades almost as fast as natural GHRH does. That limits sustained GH elevation but produces pulses closely mirroring the body's own secretory pattern — a profile some researchers consider more physiologically relevant than longer-acting alternatives.
The key clinical study put that profile to the test: nightly subcutaneous injections (10 μg/kg) for 16 weeks in men and women aged 55–71 PMID: 9141536 . Results showed sustained activation of the somatotropic axis — significantly higher nocturnal GH in both sexes, IGF-1 elevated within two weeks (though drifting back toward baseline by week 16), and increased IGFBP-3. In men specifically, researchers documented significant increases in lean body mass, improved insulin sensitivity, and enhanced general well-being and libido; skin thickness rose in both genders. The only adverse note was transient hyperlipidemia that resolved by study end.
One finding remains genuinely unexplained: the response was stronger in men than women. Candidate explanations include estrogen's modulation of GH signaling, baseline body-composition differences, and sex-specific variation in GHRH receptor density — none confirmed so far.
That same brevity cuts both ways. Daily, or more frequent, administration is required to keep the axis engaged — more physiological than CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue 's week-long presence, but far less convenient. Which raises the obvious question: what if you simply refused to let the peptide degrade?
CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue answered Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation 's central weakness with a piece of chemical engineering called the drug affinity complex (DAC). The 30-amino-acid peptide replicates GHRH's bioactive sequence but adds a maleimide linker that forms a stable amide bond with lysine residues on circulating albumin — converting the peptide into a slow-release pro-drug that lets out active analogue over days instead of minutes.
The landmark demonstration came in a 2006 randomized, double-blind, placebo-controlled trial published in the Journal of Clinical Endocrinology & Metabolism. A single injection of DAC-modified CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue produced sustained elevations in plasma GH and IGF-1 lasting 6 days or more — unprecedented for a GHRH analogue at the time PMID: 16352683 . Sixty-five healthy adults (younger group 21–40 years; older group 41–65) received single doses from 30 to 120 mcg/kg; mean plasma GH rose 2 to 10-fold above baseline depending on dose, IGF-1 climbed 1.5 to 3-fold, and both stayed elevated across the entire 28-day observation period. Side effects were mild — transient flushing, headache, water retention — with no serious adverse events reported.
At the pituitary, the mechanism matches other GHRH analogues: bind the receptor, raise cAMP, activate protein kinase A, trigger calcium-dependent granule release. Crucially, the somatostatin-mediated feedback loop remains intact — the system keeps its own braking mechanism.
Practically, the 6–8 day half-life changes the shape of research designs. Where Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation demands daily injections, CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue sustains IGF-1 elevation from a single weekly or less-frequent dose — useful for studying chronic GH-axis effects on body composition, metabolic parameters, or age-related decline.
There is also a stripped-down sibling. Without DAC — known in research circles as Modified GRF 1-29, or Mod GRF — the peptide behaves much like native GHRH, with a half-life around 30 minutes: sharper, more discrete pulses, sometimes paired with Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue when researchers want a more physiological rhythm.
Sustained elevation solves one problem and raises another: what happens when stimulation lasts days while physiology expects pulses? That tension leads directly to Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation , which split the difference deliberately.
Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation is the class's proof that a GHRH analogue can survive the entire drug-development gauntlet. Two facts set this synthetic 44-amino-acid analogue apart from everything else in this guide: it carries the most extensive clinical research dataset of any synthetic GHRH peptide, and it holds the only current, active FDA approval in the group.
That approval came in November 2010 under the brand name Egrifta (later Egrifta SV), for reducing excess abdominal visceral fat in HIV-infected patients with lipodystrophy. While Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation , CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue , and Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue remain classified as research compounds, Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation has completed Phase III trials, passed regulatory review, and entered clinical practice — albeit for a narrow, well-defined population.
Structurally, the difference from native GHRH is a trans-3-hexenoic acid group added at the N-terminus. It blocks dipeptidyl peptidase-IV (DPP-IV) cleavage, stretching the half-life to 26–38 minutes — roughly 5 to 10 times longer than native GHRH, yet still far shorter than CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue 's DAC form. The result is sustained-but-not-continuous GH stimulation, preserving a degree of physiological pulsatility.
The clinical file is robust by any standard in this class. Two pivotal Phase III randomized controlled trials and their pooled analyses showed that 26 weeks of daily subcutaneous injections significantly reduced waist circumference and visceral adipose tissue (VAT) versus placebo, alongside improvements in patient-reported body image PMID: 22298602 . Extension phases confirmed VAT improvements held over 52 weeks without adverse impact on glucose or lipid parameters.
A newer meta-analysis of randomized controlled trialsPMID: 41545261 confirmed improvements in body composition, hepatic fat, lean body mass, and IGF-1 — without serious side effects or perturbation of glucose homeostasis. Research also suggests potential relevance to nonalcoholic fatty liver disease (NAFLD), where tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation 's ability to reduce hepatic fat has generated significant interest PMID: 31237318 .
The caveats are practical: high cost, limited safety data beyond 52 weeks, and an evidence base concentrated in HIV lipodystrophy — a population whose unique metabolic profile may not generalize elsewhere.
Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation shows what full clinical development looks like. Next, meet the compound that approached the same goal from a completely different receptor.
Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue looks nothing like the others — five amino acids long (Aib-His-D-2-Nal-D-Phe-Lys-NH2), first described in 1998, and working through an entirely different receptor class. Where the three GHRH analogues act through cAMP/PKA signaling, Ipamorelin activates the GHS-R1a receptor via the Gq/11 pathway: phospholipase C rises, IP3 and diacylglycerol follow, and calcium floods out of intracellular stores.
Its claim to fame is selectivity. Earlier ghrelin mimetics — GHRP-2 and GHRP-6 GHRP-6 growth hormone secretagogue (GHS) / ghrelin receptor agonist Ghrelin mimetic hexapeptide — strongest appetite stimulation among GHRPs — stimulated GH effectively but also triggered cortisol, ACTH, and prolactin release through overlapping receptor interactions, and cortisol is catabolic: it directly undermines the anabolic goals of GH stimulation. The pivotal rat-model comparison against GHRP-2 and GHRP-6 found that at fully effective GH-releasing doses, Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue caused no statistically significant increase in cortisol or ACTH; prolactin stayed flat too, unlike with GHRP-6 PMID: 9141536 .
The kinetics suit pulse-based research. Acting on GHS-R1a receptors on pituitary somatotrophs and hypothalamic neurons, Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue produces a sharp, pulsatile GH peak roughly 30–60 minutes after administration, with levels back to baseline inside 3–4 hours — a clean, controllable spike followed by genuine recovery time.
Muscle physiology work adds another dimension: rats given Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue gained body weight and tibialis anterior muscle mass versus controls PMID: 18031173 , an effect attributed to GH/IGF-1-driven protein synthesis through the mTOR pathway. With a half-life near 2 hours, the compound behaves as a short-acting, controllable tool for modeling pulsatile GH release.
Pair it with a GHRH analogue like CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue and the two engage complementary arms simultaneously: the analogue drives baseline GH synthesis and sustained IGF-1 elevation, while Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue superimposes discrete pulses — engaging both arms of the GH secretory machinery with a rationale neither compound offers alone.
Which brings this guide to its central strategic question: what actually happens when you deliberately combine the accelerator and the amplifier?
muscle-growth fat-loss sleep
III.How They Work Together
The case for pairing a GHRH analogue with a ghrelin mimetic rests on elegant plumbing: two receptors, two signaling cascades — cAMP/PKA and Gq/IP3/calcium — converging on the same endpoint, calcium-dependent exocytosis of growth hormone from pituitary somatotrophs.
Animal research has shown co-administration produces synergistic GH release, exceeding anything either compound achieves alone PMID: 9141536 . A feedback loop explains why: GHS-R1a activation partially suppresses somatostatin, the hypothalamic brake on GH release. With the brake loosened, the GHRH analogue's drive on synthesis and release meets less opposition — the mimetic releases the brake while the analogue presses the accelerator.
In practice, **CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue + Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue ** is the most studied pairing. CJC-1295 supplies sustained baseline IGF-1 elevation from its 6–8 day half-life; Ipamorelin layers sharp, pulsatile GH peaks from its ~2-hour one. The pairing is theorized to protect receptor sensitivity over time — continuous GH exposure risks downregulation, but the pulsatile component allows recovery windows between peaks. Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation + Ipamorelin offers a more physiological alternative: closer to natural pulsatility, but demanding more frequent dosing to sustain the pattern.
Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation -plus-mimetic combinations draw less study, largely because the clinical evidence concentrates on the approved HIV lipodystrophy indication rather than combination protocols. The mechanistic logic would transfer unchanged — GHRH receptor activation plus GHS-R1a activation should yield additive or synergistic release by the same dual-pathway principle.
The honesty checkpoint matters, though: human clinical data on defined GHRH-analogue-plus-mimetic combinations is limited. Most support comes from animal models, pharmacodynamic modeling, and extrapolation across separately studied compounds. Optimal dosing ratios, timing protocols, and long-term safety profiles in humans remain unestablished by rigorous controlled trials — a gap worth carrying into the guide's conclusions.
IV.Frequently Asked Questions
Frequently Asked Questions
They activate different receptors through different intracellular signaling pathways. GHRH analogues (Sermorelin, CJC-1295, Tesamorelin) bind the GHRH receptor on pituitary somatotrophs, activating the cAMP/PKA pathway to drive GH gene transcription and release. Ghrelin mimetics (Ipamorelin) activate the GHS-R1a receptor, signaling through the Gq/IP3/calcium pathway to trigger rapid GH exocytosis. Both pathways converge on calcium-dependent GH release, but they are pharmacologically distinct — which is why combining them produces synergistic rather than merely additive effects [PMID: 16352683].
Native GHRH has a half-life of only 2–5 minutes because circulating proteases — particularly dipeptidyl peptidase-4 (DPP-4) — rapidly cleave the molecule. Each analogue addresses this vulnerability differently. Sermorelin (GHRH 1-29) retains the native cleavage site, giving it a half-life of 11–12 minutes — slightly longer than native GHRH but still very short. Tesamorelin adds a trans-3-hexenoic acid group at the N-terminus that blocks DPP-IV cleavage, extending its half-life to 26–38 minutes [PMID: 22298602]. CJC-1295 uses a completely different strategy: its DAC (drug affinity complex) modification forms a covalent bond with circulating albumin, shielding the peptide from degradation and extending its half-life to 6–8 days [PMID: 16352683].
Somatopause is the progressive, age-related decline in growth hormone secretion that begins in the third or fourth decade of life. Studies have documented that both the amplitude and frequency of pulsatile GH release decrease significantly with age [PMID: 16352683]. This decline parallels changes in body composition (increasing fat mass, decreasing lean mass), bone density, energy metabolism, and cellular repair. Growth hormone secretagogues are studied because they stimulate the pituitary's own GH production — potentially restoring more youthful pulsatile patterns — rather than bypassing the pituitary with exogenous GH injections, which suppress natural feedback mechanisms.
Earlier ghrelin mimetics like GHRP-2 and GHRP-6 stimulate GH release effectively but also trigger significant increases in cortisol, ACTH, and prolactin — hormones released through activation of overlapping receptor pathways. Cortisol is catabolic and counteracts the anabolic goals of GH stimulation. Ipamorelin was specifically engineered to minimize these off-target effects: the key pharmacological study [PMID: 16352683] compared Ipamorelin directly to GHRP-2 and GHRP-6 in rat models and confirmed that at fully effective GH-releasing doses, Ipamorelin produced no statistically significant elevation in cortisol or ACTH. This selectivity profile makes it a cleaner research tool.
Tesamorelin received FDA approval in 2010 (brand name Egrifta) specifically for reducing excess abdominal visceral fat in HIV-infected patients with lipodystrophy — a condition where antiretroviral therapy causes abnormal fat redistribution. Two pivotal Phase III randomized controlled trials demonstrated that 26 weeks of daily Tesamorelin injections significantly decreased waist circumference and visceral adipose tissue compared to placebo [PMID: 22298602]. A meta-analysis confirmed improvements in body composition, hepatic fat, lean body mass, and IGF-1 without serious side effects or glucose perturbation [PMID: 41545261]. This narrow, well-defined indication — combined with the most extensive clinical dataset of any GHRH analogue — earned it regulatory approval. It is not approved for general anti-aging or performance use.
The synergy arises because the two compound classes activate different receptor pathways that converge on the same endpoint — calcium-dependent GH exocytosis. Additionally, GHS-R1a activation by the ghrelin mimetic partially suppresses somatostatin, the natural inhibitor of GH release. With somatostatin suppressed, the GHRH analogue's drive on GH production encounters less opposition. Animal research confirms that GHRH analogue + ghrelin mimetic combinations produce GH release exceeding the sum of either compound alone [PMID: 21480850]. In effect, one pathway removes the brake while the other presses the accelerator.
The evidence levels vary substantially. Tesamorelin has the strongest evidence: Phase III RCTs demonstrating visceral fat reduction over 26–52 weeks in HIV lipodystrophy, confirmed by meta-analysis [PMID: 22298602, PMID: 41545261]. CJC-1295 has a single published Phase I study showing 2–10-fold GH elevation and 1.5–3-fold IGF-1 elevation sustained for 6+ days in 65 healthy adults [PMID: 16352683]. Sermorelin has older clinical data including a 16-week study in age-advanced adults showing GH axis activation and gender-specific body composition improvements [PMID: 9141536]; it was also FDA-approved for pediatric GH deficiency before commercial withdrawal. Ipamorelin has primarily preclinical data — its selectivity was established in rat models [PMID: 21480850] and muscle effects documented in animal studies [PMID: 9141536].
With exogenous GH injections, receptor downregulation is a documented concern because receptors are continuously exposed to elevated GH levels. Growth hormone secretagogues work differently: they stimulate the pituitary to release GH in patterns that more closely mimic natural pulsatility. Ipamorelin, with its short half-life, produces acute peaks followed by return to baseline — maintaining recovery periods for receptor resensitization. CJC-1295's sustained elevation is a different profile and may be more analogous to continuous exposure. The combination of a long-acting GHRH analogue with a short-acting ghrelin mimetic is theorized to balance sustained IGF-1 support with pulsatile receptor stimulation, though definitive long-term human data on receptor adaptation is not available.
The largest natural GH pulse occurs within the first few hours of sleep onset, specifically during slow-wave (deep) sleep stages 3 and 4. This nocturnal pulse accounts for roughly 70% of daily GH secretion in young adults and is driven by a GHRH surge from the hypothalamus [PMID: 9141536]. With aging, both slow-wave sleep duration and the associated GH pulse amplitude decline in parallel. GHRH analogues administered before sleep may augment this nocturnal pulse by amplifying the pituitary's response to the hypothalamic GHRH signal. Systematic polysomnographic studies measuring sleep architecture changes in response to specific secretagogues have not been published.
Regulatory status varies significantly. Tesamorelin (Egrifta/Egrifta SV) is FDA-approved for HIV-associated lipodystrophy — the only compound in this guide with active pharmaceutical approval. Sermorelin was FDA-approved as Geref for pediatric GH deficiency but was withdrawn from the market in 2008 for commercial (not safety) reasons; it remains available through compounding pharmacies. CJC-1295 and Ipamorelin are not approved by the FDA, EMA, or equivalent regulatory bodies; they are classified as research chemicals. All four compounds are prohibited by WADA (World Anti-Doping Agency) under the category of peptide hormones and growth factor analogues. The FDA has taken enforcement action against compounding pharmacies dispensing unapproved peptides as drugs.
V.Summary
Four compounds, one goal, four engineering philosophies. Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation delivers the shortest, most physiologically natural pulse — and demands frequent dosing for it. CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue stretches the GHRH signal to days through albumin binding, sustaining IGF-1 from infrequent injections. Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation splits the difference in duration while standing alone as the only member with active FDA approval for clinical use. Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue attacks from a different receptor entirely, producing selective, short-acting GH pulses without cortisol disruption.
The mechanistic case for combining a GHRH analogue with a ghrelin mimetic is scientifically sound: dual-pathway activation produces synergistic GH release while preserving natural feedback mechanisms. It is why researchers studying the GH axis so often reach for pairs rather than single agents.
What the literature clearly supports: real pharmacological compounds with documented effects on GH and IGF-1 levels in both preclinical and clinical settings. What it does not yet settle: whether sustained GH-axis stimulation produces clinically meaningful long-term benefits for body composition, aging, or metabolic health beyond the specific populations already studied.
Primary literature through PubMed remains the authoritative source as new findings land. For pairing specifics, see the Growth Hormone Stack guide; for head-to-head analysis, see [CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue vs Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue ](/en/compare/cjc-1295-vs-ipamorelin/). Whichever thread you pull next, you now hold the receptor map that explains why these four compounds behave so differently.
Tesamorelin 
Ipamorelin 
Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation began as a trimming exercise. Native GHRH runs 44 amino acids, but research established that the first 29 carry full receptor-binding and GH-releasing activity — so researchers synthesized that minimal segment, GHRH 1-29, as the smallest fully functional unit of the system.
CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue 's week-long presence, but far less convenient. Which raises the obvious question: what if you simply refused to let the peptide degrade?